

In the claims:

The listing of claims below will replace all previous versions, and listings, of claims in the application.

1. A method of identifying a test compound useful for the treatment of an impaired maximum gastric accommodation capacity, wherein the method comprises:

administering a test compound to a non-human animal identified to have an impaired maximum gastric accommodation capacity;

determining the maximum gastric accommodation capacity in the animal following administration of the compound; and

comparing the maximum gastric accommodation capacity of the animal before and after administration of the test compound, wherein an increase in the accommodation capacity in the animal following administration of the compound is indicative that the compound is useful for the treatment of impaired maximum gastric accommodation capacity.

2. (original) The method of claim 1, wherein the non-human animal is a rat or a dog.

3. (currently amended) The method of ~~claim 1~~ claim 2, wherein the rat is a Wistar Kyoto rat.

4. (original) The method of claim 1, wherein the compound is a nitrogen oxide synthase (NOS) inhibitor, a 5HT-3 agonist, a 5HT-4 antagonist, an alpha-2 agonist, a glucagon or a cholinergic agonist or antagonist.

5. (original) The method of claim 1 wherein the compound is administered orally.

6. (original) A compound identified by the method of claim 1.

7. (cancelled)

8. (currently amended) A method for the treatment of functional dyspepsia, comprising administering to a subject in need of such treatment an effective amount of the compound identified by the method of claim 1.

9. (currently amended) A pharmaceutical formulation comprising the compound identified by the method of claim 1 in association with pharmaceutically acceptable carriers, diluents and/or excipients.

10-13. (cancelled)